BBV152 (@BBV152) header
BBV152 (@BBV152) profile picture

Step by step.... Till fruition

Joined February 2022
Photo by BBV152 (@BBV152)Photo by BBV152 (@BBV152)Photo by BBV152 (@BBV152)Photo by BBV152 (@BBV152)Photo by BBV152 (@BBV152)Photo by BBV152 (@BBV152)Photo by BBV152 (@BBV152)Photo by BBV152 (@BBV152)Photo by BBV152 (@BBV152)
BBV152 retweeted
Ocugen CEO @drsmusunuri joined @BBC Correspondent @JamesTGallagher at Cell & Gene Leaders Live to discuss our modifier gene therapy platform and its potential to address vision loss across a broader patient population. #GeneTherapy #Biotech $OCGN
18
2
102
3,494
BBV152 retweeted
Today, at the @Stifel 2026 Healthcare Conference, Ocugen CEO @drsmusunuri highlighted our novel modifier #genetherapy platform and three Phase 3 investigational assets in NYC. #Biotech Watch the replay: bit.ly/4zdvc2f $OCGN
22
3
81
4,240
Our partnership with Celairis Therapeutics marks our third strategic regional agreement for OCU400 and another important step in advancing our global access strategy. We remain focused on bringing our potential one-time gene therapy closer to patients around the world.
Ocugen is expanding the potential reach of #OCU400 for #retinitispigmentosa through an exclusive licensing agreement with Celairis Therapeutics for #commercialization across Australia, New Zealand, and ASEAN markets with an estimated 725M+ people, following potential U.S. approval. $OCGN 🔗bit.ly/3Vk1ue6
30
3
113
2,069
Thank you to CMS Administrator @DrOzCMS, Deputy Administrator @AbeSutton, and the @CMSInnovates Center team for expanding the Cell and Gene Therapy Access Model beyond sickle cell disease. An important step toward greater patient access and continued biotech innovation.
At Cleveland Clinic today, CMS Innovation Center Director Abe Sutton, @DrOzCMS, and @FDA_KyleD announced that CMS will invite manufacturers of other cell and gene therapies to apply to the CGT Access Model. Learn more: go.cms.gov/CGT
16
5
64
3,548
BBV152 retweeted
Ocugen is taking part in two key industry events this November! CEO @drsmusunuri will participate in the Stifel 2026 Healthcare Conference and Cell & Gene Leaders Live 2026. Read more: bit.ly/4ss67Pm #HealthcareInnovation #GeneTherapy $OCGN
16
5
76
4,928
BBV152 retweeted
Ocugen and Roots Pharmaceutical have completed a licensing agreement for #OCU400 in MENA, advancing global commercialization. Terms include up to $4M in upfront and initial development milestones, $255M in potential sales milestones, and 22% royalties on net sales. $OCGN Read more: bit.ly/47OVm06
28
3
126
6,399
BBV152 retweeted
An important milestone at #AAO2026! During the @aao_ophth Annual Meeting, Raj K. Maturi, MD, presented 12-month safety and efficacy results from our Phase 2 ArMaDa trial evaluating #OCU410 for #geographicatrophy, supporting its continued advancement in Phase 3. #GeneTherapy $OCGN Read more from @ophth_advisor: bit.ly/4e9Qh67
27
3
102
5,278
BBV152 retweeted
Ocugen CEO @drsmusunuri will participate in @HCWCO: #Biotech on Tap and the Cell & Gene Meeting on the Mesa this October, sharing updates on our gene therapy programs with the investment community. @alliancerm #CGMesa26 #InvestorRelations $OCGN Read: bit.ly/3VC4ana
14
2
69
5,183
#OCU400, our #genetherapy for #retinitispigmentosa, received provisional approval and priority designation from the LARTA Board in the Bahamas, a significant step as we advance our mission globally. @MOHW242 $OCGN #CommercialPricing 🔗bit.ly/4xNFDZR
9
1
52
1,059
BBV152 retweeted
$OCGN Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration More Info: pryzm.ozmosi.com/product/270…
2
31
661
Millions globally are awaiting rescue from blindness caused by #geographicatrophy secondary to #dAMD. Thank you to the @FDA for its collaboration, from our End-of-Phase 2 meeting to RMAT designation and now Phase 3 initiation. Proud of the Ocugen team! #Biotech #OCU410
Today, CEO @drsmusunuri announced a major advancement for #OCU410 and #geographicatrophy: the first patient dosed in our global Phase 3 trial. We are one step closer to a potential one-time treatment for life and our target of 3 BLAs by 2028. 🔗bit.ly/4qNMBMk $OCGN
22
1
97
3,945
BBV152 retweeted
Today, CEO @drsmusunuri announced a major advancement for #OCU410 and #geographicatrophy: the first patient dosed in our global Phase 3 trial. We are one step closer to a potential one-time treatment for life and our target of 3 BLAs by 2028. 🔗bit.ly/4qNMBMk $OCGN
39
2
141
11,624
BBV152 retweeted
Momentum across our #genetherapy pipeline continues. At the Canaccord Growth Conf., CEO @drsmusunuri noted 2 BLAs targeted next year, the upcoming Phase 3 #OCU410 trial, and no serious adverse events reported to date related to Ocugen’s gene therapies. 🔗 bit.ly/45WvRcc
30
1
99
5,376
BBV152 retweeted
Many vision conditions develop without early warning signs. Routine eye exams can help detect changes early. Stay proactive about your eye health and encourage your loved ones to do the same. #EyeHealth #ProtectYourVision
15
75
2,737
$OCGN Keep spreading the word! So many people need this!
When Manny Fernandez enrolled in a gene therapy clinical trial for retinitis pigmentosa (RP), he hoped his participation might one day help someone else. What he didn't expect was to regain a small part of the vision he had lost—an experience that gave him renewed hope for the future. Today, Manny is sharing his journey, from decades of adapting to vision loss to becoming one of the first people to receive this experimental treatment, and encouraging others to learn more about clinical trials. Watch and read Manny's full Beacon Story on our website at: FightingBlindness.org/storie… This Beacon Story is sponsored by @Ocugen. Video Description: Manny speaks directly to the camera about his experience with RP and the improvements in his vision, with clips of him walking outside.
6
46
1,652
Behind every breakthrough is a patient, a family, and a story. At Ocugen, we remain committed and are humbled by the potential impact our science can have on people's lives. Moments like these reinforce our purpose and create hope for patients and families around the world!
When Manny Fernandez enrolled in a gene therapy clinical trial for retinitis pigmentosa (RP), he hoped his participation might one day help someone else. What he didn't expect was to regain a small part of the vision he had lost—an experience that gave him renewed hope for the future. Today, Manny is sharing his journey, from decades of adapting to vision loss to becoming one of the first people to receive this experimental treatment, and encouraging others to learn more about clinical trials. Watch and read Manny's full Beacon Story on our website at: FightingBlindness.org/storie… This Beacon Story is sponsored by @Ocugen. Video Description: Manny speaks directly to the camera about his experience with RP and the improvements in his vision, with clips of him walking outside.
17
2
83
6,547